PFO
MYGN icon

Pathstone Family Office’s Myriad Genetics MYGN Stock Holding History

Pathstone Family Office’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,354
Closed -$207K – 1399
2022
Q4 		$207K Buy
+5,354
New +$99.8K ﹤0.01% 1374
2021
Q1 		– Sell
-15
Closed – – 1096
2020
Q4 		$0 Hold
15
– – ﹤0.01% 1270
2020
Q3 		$0 Hold
15
– – ﹤0.01% 926
2020
Q2 		$0 Sell
15
-72
-83% -$1.02K ﹤0.01% 887
2020
Q1 		$1K Buy
+87
New +$1.84K ﹤0.01% 723
2019
Q2 		– Sell
-89
Closed -$3K – 809
2019
Q1 		$3K Hold
89
– – ﹤0.01% 699
2018
Q4 		$3K Buy
+89
New +$3.2K ﹤0.01% 424

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Pathstone Family Office's MYGN Position: Q1 2023 in Review

Pathstone Family Office sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 5,354 shares — an estimated $207K sold.

Pathstone Family Office first reported a position in MYGN in Q4 2018 and held it in 7 quarters. The position peaked at $207K in Q4 2022. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

  • Pathstone Family Office reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
  • Pathstone Family Office sold 5,354 Myriad Genetics shares in Q1 2023, an estimated $207K.
  • Pathstone Family Office first reported a position in Myriad Genetics in Q4 2018 and held it in 7 quarters.
  • Pathstone Family Office's Myriad Genetics position peaked at $207K in Q4 2022.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.